8-K: Aspire Biopharma Converts $1.75M Debt to Equity

Aspire Biopharma Holdings, Inc. entered into agreements to exchange approximately $1.75 million in debt for common stock with certain holders, aiming to strengthen its balance sheet.

Summary

• Aspire Biopharma Holdings, Inc. (ASBP) entered into Exchange Agreements on January 1, 2026, with certain debt holders.
• The agreements facilitate the exchange of approximately $1.75 million in debt for shares of the company's common stock (Exchange Shares).
• This debt originated from subscription agreements dated March 4, 2024, and May 9, 2024, incurred by the company's predecessor, PowerUp Acquisition Corp., with the debt holders being Sponsors of PowerUp's initial public offering.
• The Exchange Price for the common stock will be the closing price of the company's Common Stock on the trading day immediately prior to an Exchange Notice, less one cent ($0.01) as an administrative fee.
• Holders can submit up to four Exchange Notices, with each of the first three tranches not exceeding thirty percent (30%) of the applicable holder's Outstanding Balance. The fourth tranche will cover the remaining balance plus any Outstanding Balance Adjustments.
• All Exchange Notices must be submitted by January 31, 2026, subject to reasonable extensions if Exchange Shares are not immediately freely tradeable.
• The Exchange Shares will be delivered as freely tradeable, without transfer restrictions or restrictive legends.
• The company may repay part or all of any holder's Outstanding Balance upon a financing exceeding $3,000,000.
• In such a financing, a holder may elect to receive cash proceeds equal to twenty five percent (25%) of their Outstanding Balance, or up to 33.33% of the aggregate financing proceeds.
• The securities are being issued in reliance upon an exemption from registration under Section 3(a)(9) of the Securities Act and Regulation D.

Sentiment

Score: 6

Explanation: The debt-to-equity conversion is a necessary step to clean up the balance sheet and reduce liabilities, which is generally positive for financial stability. However, it comes with the negative impact of shareholder dilution and the existence of material weaknesses in internal controls. The optional cash repayment clause in future financing offers some flexibility.

Positives

• Reduces approximately $1.75 million in outstanding debt, improving the company's balance sheet and reducing future interest obligations (though the original debt was interest-free, it still represents a liability).
• Converts a liability into equity, potentially strengthening the company's financial structure.
• Provides flexibility for the company to repay debt in cash if a significant financing event occurs.

Negatives

• The conversion of debt into common stock will result in dilution for existing shareholders.
• The Exchange Price is set at a discount (closing price minus $0.01), which could be seen as unfavorable for existing shareholders.
• The administrative fee of $0.01 per share effectively means the company is issuing shares at a slightly lower price than the market closing price.
• The 'Outstanding Balance Adjustment' mechanism could potentially increase the total number of shares issued if the weighted average sale price is lower than the final day trading price, leading to further dilution.

Risks

• Shareholder Dilution: The issuance of new common stock to convert debt will dilute the ownership percentage of existing shareholders.
• Market Price Volatility: The Exchange Price is tied to the closing price of the common stock, meaning significant fluctuations in the stock price could impact the number of shares issued and the effective value of the conversion.
• Material Weaknesses in Internal Control Over Financial Reporting: The company disclosed material weaknesses in its internal control over financial reporting (as per Schedule 3.17), which could lead to financial misstatements or operational inefficiencies.
• Future Capital Raise Impact: While a financing event could allow for cash repayment, it also introduces uncertainty regarding the terms and potential further dilution from such a raise.

Future Outlook

The company anticipates completing the debt-to-equity exchanges by January 31, 2026. There is a possibility of a future financing event exceeding $3,000,000, which could trigger optional cash repayment of the remaining outstanding debt to holders.

Management Comments

• The report was signed by Ernest Scheidemann, Chief Financial Officer, on behalf of Aspire Biopharma Holdings, Inc.

Industry Context

Biopharma companies, particularly those in early stages or post-SPAC mergers, often utilize debt-to-equity conversions as a mechanism to manage liabilities, improve balance sheet health, and preserve cash for operational activities, especially R&D. This move aligns with strategies to de-risk the financial structure, though it typically comes at the cost of shareholder dilution.

Corporate Governance

Related Party Transactions

• The debt holders involved in the exchange were Sponsors of PowerUp Acquisition Corp.'s initial public offering, the company's predecessor, indicating a related party transaction.

Stakeholder Impact

• Shareholders: Will experience dilution due to the issuance of new common stock.
• Debt Holders (Sponsors): Will convert their debt into equity, becoming shareholders and potentially benefiting from future stock price appreciation, while also bearing equity risk.
• Company: Benefits from a stronger balance sheet by reducing debt and preserving cash.

Next Steps

• Holders to submit Exchange Notices by January 31, 2026.
• Company to issue Exchange Shares within one business day of receiving an Exchange Notice.
• Company to file a Current Report on Form 8-K by 9:00 a.m. (New York City time) on January 6, 2026, disclosing the agreement.

Key Dates

Keywords

Aspire Biopharma, ASBP, Debt to Equity, Exchange Agreement, Common Stock, Dilution, SEC Filing, Biopharma, Capital Raise, Corporate Finance, Balance Sheet Restructuring, PowerUp Acquisition Corp.